LANXESS Aktiengesellschaft (LXS)
XETRA Stock Exchange · Germany · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 12.79 |
|---|---|
| 52-week range | 10.97 – 21.89 |
| Return, 1 month / 3 months | −4.6% / −16.0% |
| Return, 1 year / 3 years | −39.7% / −37.0% |
| Trend | Below its 200-day average |
| RSI (14) | 47 |
| Volatility (1 year) | 53.5% |
| Worst drawdown (1 year) | -46.1% |
| Average daily value traded | 7.08M EUR |
| Dividend yield | 0.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Lanxess is a specialty chemicals company based in Germany. It makes chemical intermediates, additives, pigments and materials protection products used in plastics, coatings, lubricants and construction. Its customers are industrial manufacturers and processors in sectors such as automotive, building and consumer goods. The company also supplies flame retardants and disinfectant and water-treatment chemicals, and it operates production sites in several countries, serving industrial markets around the world.
The shares are listed on the XETRA Stock Exchange in Germany under the code LXS, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
LANXESS Aktiengesellschaft (LXS) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 12.79 on 19 October 2026.
Its price-based Market X-Ray is 29 out of 100 (a weak price profile), ranking 575 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 39.7% and over the last three months it fell 16.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 16 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -20.7% | ||
| From 52-week high | -40.5% | ||
| Momentum | 14 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -16.0% | ||
| 6-month return | -29.6% | ||
| 12-month return, skipping the last month | -36.7% | ||
| Risk (lower is better) | 21 · Weak | Volatile, with deep drawdowns. | |
| Volatility (1 year) | 53.5% | ||
| Worst drawdown (1 year) | -46.1% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 7.08M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 31 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.8% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Risk (lower is better): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.8% |
|---|---|
| 1 month | −4.6% |
| 3 months | −16.0% |
| 6 months | −29.6% |
| 1 year | −39.7% |
| 3 years | −37.0% |
| 5 years | −75.4% |
Signals
| 50-day / 200-day average | 13.82 / 16.13 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.54 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 May 2026 | EUR 0.1000 |
| 23 May 2025 | EUR 0.1000 |
| 27 May 2024 | EUR 0.1000 |
| 25 May 2023 | EUR 1.0500 |
| 26 May 2022 | EUR 1.0500 |
| 20 May 2021 | EUR 1.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.